Treatment of Anemia with Darbepoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study

被引：1
|
作者：
Villegas, Ana [1 ]
Arrizabalaga, B. [2 ]
Fernandez-lago, C. [3 ]
Mouzo, M. [4 ]
Mayans, Jr [5 ]
Gonalez-Porras, Jr [6 ]
Duarte, Rafael [7 ]
Remacha, Angel Francisco [8 ]
Luno, Elisa [9 ]
Gasquet, J. A.
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] Hosp Cruces, Dept Haematol, Bilbao, Spain
[3] Hosp Juan Canalejo, Dept Haematol, La Coruna, Spain
[4] Complejo HU Vigo Xeral Cies, Dept Haematol, Vigo, Spain
[5] Hosp Arnau Vilanova, Dept Haematol, Valencia, Spain
[6] Hosp Univ Salamanca, Salamanca, Spain
[7] Hosp Duran & Reynals ICO, Bellvitge, Spain
[8] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[9] Hosp Univ Cent Asturias, Oviedo, Spain
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
10.1182/blood.V112.11.3451.3451
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1184 / 1184
页数：1
相关论文
共 50 条
  • [31] Evaluation of VEGF and VEGFR gene expression as prognostic markers in low and intermediate-1 risk patients with myelodysplastic syndromes
    Kalitin, Nikolay
    Dudina, Galina
    Kostritsa, Natalia
    Sivirinova, Anastasiya
    Karamysheva, Aida
    ONCOLOGY LETTERS, 2023, 25 (03)
  • [32] ARCADE (20090160): A randomized controlled trial of darbepoetin alpha in anemic patients with low or intermediate-1 risk myelodysplastic syndrome (MDS)
    Gasal, E.
    Pan, C.
    Tankersley, C.
    LEUKEMIA RESEARCH, 2013, 37 : S166 - S167
  • [33] Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study
    Valcarcel, David
    Sanz, Guillermo
    Ortega, Margarita
    Nomdedeu, Benet
    Luno, Elisa
    Diez-Campelo, Maria
    Teresa Ardanaz, Maria
    Pedro, Carmen
    Montoro, Julia
    Collado, Rosa
    Andreu, Rafa
    Marco, Victor
    Teresa Cedena, Maria
    de Paz, Raquel
    Tormo, Mar
    Xicoy, Blanca
    Ramos, Fernando
    Bargay, Joan
    Gonzalez, Bernardo
    Brunet, Salut
    Antonio Munoz, Juan
    Gomez, Valle
    Bailen, Alicia
    Sanchez, Joaquin
    Merchan, Brayan
    del Canizo, Consuelo
    Vallespi, Teresa
    LANCET HAEMATOLOGY, 2015, 2 (06): : E260 - E266
  • [34] 5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program
    Musto, Luca Maurillo
    Spagnoli, Alessandra
    Gozzini, Antonella
    Rivellini, Flavia
    Tatarelli, Caterina
    Lunghi, Monia
    Fili, Carla
    Orciuolo, Enrico
    Ciuffreda, Lucia
    Vigna, Ernesto
    Della Cioppa, Paola
    Candoni, Anna
    Ferrero, Dario
    Palmieri, Salvatore
    Palumbo, Giuseppe
    Di Renzo, Nicola
    Oliva, Esther
    Sanpaolo, Grazia
    Pastore, Domenico
    Tonso, Anna
    Santagostino, Alberto
    Rocco, Stefano
    Villani, Oreste
    D'Auria, Fiorella
    D'Arco, Alfonso Maria
    Gaidano, Gianluca
    Galimberti, Sara
    Russo, Domenico
    Venditti, Adriano
    Aloe-Spiriti, Maria Antonietta
    Leone, Giuseppe
    Santini, Valeria
    BLOOD, 2008, 112 (11) : 926 - 927
  • [35] BIOSIMILAR ERYTHROPOIETIN ALFA FOR THE THERAPY OF ANEMIA IN "LOWER RISK" MYELODYSPLASTIC SYNDROMES. INTERIM RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY OF THE "RETE EMATOLOGICA LOMBARDA" (EPOREL)
    Pelizzari, A. M.
    Borlenghi, E.
    Mariotti, J.
    Riva, M.
    Molteni, A.
    Lambertenghi, D.
    Passi, A.
    Orlando, V.
    Lamorgese, C.
    Morra, E.
    HAEMATOLOGICA, 2016, 101 : 775 - 775
  • [36] ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study
    Platzbecker, Uwe
    Germing, Ulrich
    Giagounidis, Aristoteles
    Goetze, Katharina
    Kiewe, Philipp
    Mayer, Karin
    Ottman, Oliver
    Radsak, Markus P.
    Wolff, Thomas
    Haase, Detlef
    Hankin, Monty
    Wilson, Dawn M.
    Laadem, Adberrahmane
    Sherman, Matthew L.
    Attie, Kenneth M.
    BLOOD, 2014, 124 (21)
  • [37] Once-weekly recombinant erythropoietin plus thalidomide for the anemia of low-to-intermediate risk myelodysplastic syndromes.
    Musto, P
    Falcone, A
    Sanpaolo, G
    Bodenizza, C
    La Sala, A
    Carella, AM
    BLOOD, 2003, 102 (11) : 327B - 328B
  • [38] Darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: Interim results after 27/28 weeks.
    Paguette, R.
    Gabrilove, J.
    Lyons, R.
    Mushtaq, C.
    Sekeres, M.
    Lam, H.
    Dreiling, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 352S - 352S
  • [39] Effectiveness of darbepoetin alfa vs epoetin alfa in patients with anemia resulting from myelodysplastic syndrome (MDS): results of a retrospective cohort study.
    Patten, JE
    Sullivan, T
    Mun, Y
    Wallace, J
    PHARMACOTHERAPY, 2005, 25 (03): : 468 - 468
  • [40] Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome
    Marcel Merchan, Brayan
    Ortega, Margarita
    Jose Llamas-Poyato, Mara
    Cortes, Montserrat
    Arnan, Montserrat
    Cervero, Carlos
    Montoro, Julia
    Gimenez, Teresa
    Lopez, Mara
    Arenillas, Leonor
    Valcarcel, David
    BLOOD, 2014, 124 (21)
12345